



## Xarelto<sup>®</sup> (rivaroxaban) – Expanded indication

- On October 30, 2017, [Janssen Pharmaceuticals announced](#) the FDA approval of [Xarelto \(rivaroxaban\)](#) 10 mg for the reduction in the risk of recurrence of deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months.
- Xarelto is also indicated:
  - To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  - For the treatment of DVT
  - For the treatment of PE
  - For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.
- The expanded indication for Xarelto was based on the EINSTEIN CHOICE study. Patients who had completed 6 - 12 months of anticoagulant treatment for DVT and/or PE received Xarelto 10 or 20 mg once daily or 100 mg aspirin once daily. Because the benefit-risk assessment favored the 10 mg dose vs. aspirin compared to the 20 mg dose vs. aspirin, only the data for 10 mg dose is reported.
  - Xarelto 10 mg was superior vs. aspirin 100 mg for the primary composite endpoint of time to first occurrence of recurrent DVT or nonfatal or fatal PE (1.2% vs. 4.4%, respectively; Hazard ratio = 0.26; 95% CI: 0.14, 0.47; p < 0.0001).
- Xarelto carries a boxed warning stating that premature discontinuation of Xarelto increases the risk of thrombotic events and spinal/epidural hematoma.
- The recommended dosage of Xarelto for the expanded indication is 10 mg orally once daily with or without food, after at least 6 months of standard anticoagulant treatment.
- Consult Xarelto's drug label for recommended dosing for all other indications.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.